Press Release

  View printer-friendly version

<<  Back

Cytokinetics to Present at November Healthcare Conferences

SOUTH SAN FRANCISCO, CA, Nov 03, 2009 (MARKETWIRE via COMTEX) -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that members of its Executive team are scheduled to present at the following four upcoming healthcare conferences throughout the month of November:

Merriman Curhan Ford's 6th Annual Investor Summit 2009 Date: Tuesday, November 10, 2009 Time: 11:20 a.m. Eastern Time

Location: Hotel Sofitel, New York, New York Presenter: Robert I. Blum, President and Chief Executive Officer

Canaccord Adams' 3rd Annual Cardiovascular Conference Date: Tuesday, November 10, 2009 Time: 2:30 p.m. Pacific Time Location: Nikko Hotel, San Francisco, California Presenters: Sharon A. Barbari, EVP Finance and Chief Financial Officer Andrew A. Wolff, M.D., SVP Clinical Research and Chief Medical Officer

2009 Credit Suisse Healthcare Conference Date: Wednesday, November 11, 2009 Time: 4:30 p.m. Mountain Time Location: Arizona Biltmore Hotel, Phoenix, Arizona Presenter: Robert I. Blum, President and Chief Executive Officer

Lazard Capital Markets' 6th Annual Healthcare Conference Date: Tuesday, November 17, 2009 Time: 11:30 a.m. Eastern Time

Location: The St. Regis Hotel, New York, New York Presenter: Robert I. Blum, President and Chief Executive Officer

Interested parties may access the live audio webcast of these presentations and replays by visiting the Investor Relations section of the Cytokinetics website at The webcast replay of these presentations will be archived on the Presentations page within the Investor Relations section of Cytokinetics' website for two weeks following the completion of the event.

About Cytokinetics

Cytokinetics is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics that modulate muscle function for the potential treatment of serious diseases and medical conditions. Cytokinetics' lead drug candidate from its cardiac muscle contractility program, omecamtiv mecarbil (formerly CK-1827452), is in Phase II clinical development for the potential treatment of heart failure. Amgen Inc. holds an exclusive license worldwide (excluding Japan) to develop and commercialize omecamtiv mecarbil and related compounds, subject to Cytokinetics' specified development and commercialization participation rights. Cytokinetics is independently developing CK-2017357, a skeletal muscle activator, as a potential treatment for diseases and conditions associated with aging, muscle wasting or neuromuscular dysfunction. CK-2017357 is in Phase I clinical development. Cytokinetics is also conducting non-clinical development of compounds that inhibit smooth muscle contractility and which may be useful as potential treatments for diseases and conditions such as systemic hypertension, pulmonary arterial hypertension or bronchoconstriction. In addition, prior Cytokinetics' research generated three anti-cancer drug candidates in Phase I clinical development: ispinesib, SB-743921 and GSK-923295. Cytokinetics is seeking a partner for ispinesib and SB-743921 and GSK-923295 is being developed under Cytokinetics' collaboration with GlaxoSmithKline. All of these drug candidates and potential drug candidates have arisen from Cytokinetics' research activities and are directed towards the cytoskeleton. The cytoskeleton is a complex biological infrastructure that plays a fundamental role within every human cell. Additional information about Cytokinetics can be obtained at

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act"). Cytokinetics disclaims any intent or obligation to update these forward-looking statements, and claims the protection of the Act's safe harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to planned presentations and the properties and potential benefits of Cytokinetics' drug candidates and potential drug candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approval and production of Cytokinetics' drug candidates and potential drug candidates that could slow or prevent clinical development or product approval, including risks that current and past results of clinical trials or preclinical studies may not be indicative of future clinical trials results, Cytokinetics' drug candidates and potential drug candidates may have unexpected adverse side effects or inadequate therapeutic efficacy and Cytokinetics may be unable to obtain the additional funding necessary to advance some or all of its research and development programs. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.

Cytokinetics, Incorporated
Christopher S. Keenan
Director, Investor and Media Relations
(650) 624-3000

SOURCE: Cytokinetics, Inc.